GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Q3 FY27 Profit Rs. 766 Million, Revenue Rs. 2,631 Million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 28 Oct 2026, 06:52 PM IST  ·  BSE ID: d635755e-5129-426e-8a70-a522f3ee3f23
View Original BSE Filing (PDF)
💡
In Simple Terms
Sanofi Consumer Healthcare India reported higher sales and profit for the September quarter and the first nine months of 2026.
🤖 AI Summary
  • Sanofi Consumer Healthcare India Ltd. approved Q3 FY27 unaudited financial results for the period ended September 30, 2026.
  • Revenue from Operations for Q3 FY27 was ₹2,631 Million, a 12% increase from ₹2,339 Million in Q3 FY26.
  • Profit for the period in Q3 FY27 reached ₹766 Million, marking a 22% growth from ₹629 Million in Q3 FY26.
  • Nine-month FY27 Revenue from Operations stood at ₹7,280 Million, up 16% from ₹6,274 Million in the prior period.
  • Basic and diluted earnings per share (EPS) for Q3 FY27 was ₹33.26, compared to ₹27.31 in Q3 FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Quarter ended 30.09.2026)
₹2,631 Million
12%
Profit for the period (Quarter ended 30.09.2026)
₹766 Million
22%
Basic and diluted earnings per share (Quarter ended 30.09.2026)
₹33.26
21.78%
Revenue from Operations (Nine Months ended 30.09.2026)
₹7,280 Million
16.04%
Profit for the period (Nine Months ended 30.09.2026)
₹2,132 Million
22.81%
🏢 How This Affects the Company
📈
Business Impact
The company reported 19% domestic sales growth and 19% export sales growth for the nine months ended September 30, 2026, indicating expanded market penetration and demand for its products.
💰
Financial Impact
Profit for the period increased by 22% in Q3 FY27 to ₹766 Million and by 23% for the nine months to ₹2,132 Million, strengthening the company's profitability metrics.
⚙️
Operational Impact
Continued focus on brand building, expanding distribution footprint, and Healthcare Professional reach are cited as factors supporting volume expansion and market share gains.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with Q3 FY27 Basic and diluted EPS at ₹33.26, compared to ₹27.31 in Q3 FY26, impacting perceived value.
🔍
Management Signal
Management highlighted disciplined execution, portfolio strength, and investments in brand building and distribution as drivers of current performance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q4 FY27 results — monitor full year performance and growth trends.
Review of domestic and export sales figures in future filings.
Management commentary on brand building and distribution investments.
LOW RISK No new risks identified; previous year's comparability issue is noted.
💡 Investor Takeaway
Sanofi Consumer Healthcare India Ltd reported Q3 FY27 Revenue from Operations of ₹2,631 Million, a 12% YoY increase, and Profit for the period of ₹766 Million, up 22% YoY. For the nine months ended September 30, 2026, Revenue from Operations was ₹7,280 Million, rising 16% YoY.
⚖️ Strengths & Concerns

✅ Positives

  • Q3 FY27 Revenue from Operations grew 12% YoY to ₹2,631 Million, indicating sustained sales momentum.
  • Q3 FY27 Profit for the period increased by 22% YoY to ₹766 Million, demonstrating improved profitability.

⚠️ Concerns

  • Note 3 indicates prior period results for nine months ended September 30, 2025 are not fully comparable due to product recalls and relaunches.
  • Purchases of stock in trade for Q3 FY27 decreased to ₹116 Million from ₹260 Million in Q3 FY26, suggesting potential shifts in inventory strategy.
📅 Company Track Record
Sanofi Consumer Healthcare India Ltd. emerged as a distinct legal entity following its demerger from Sanofi India Limited on June 1, 2024. Q1 FY27 profit was ₹688 Million on revenue of ₹2,357 Million. Full-year FY26 profit was ₹2,401 Million with Q4 domestic sales recovering 15.5% after product relaunches.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Sanofi Consumer Healthcare India's Revenue from Operations in Q3 FY27?
Sanofi Consumer Healthcare India's Revenue from Operations for the quarter ended September 30, 2026, was ₹2,631 Million.
What was the Profit for the period for Sanofi Consumer Healthcare India in Q3 FY27?
The Profit for the period for Sanofi Consumer Healthcare India in Q3 FY27 (quarter ended September 30, 2026) was ₹766 Million.
What was Sanofi Consumer Healthcare India's Basic and diluted EPS for Q3 FY27?
Sanofi Consumer Healthcare India's Basic and diluted earnings per share for the quarter ended September 30, 2026, was ₹33.26.
How did the nine-month FY27 Revenue from Operations compare to the prior period?
For the nine months ended September 30, 2026, Revenue from Operations was ₹7,280 Million, an increase of 16% from ₹6,274 Million in the nine months ended September 30, 2025.
Is the financial data comparable year-over-year due to product recalls?
Note 3 states that the results are not fully comparable with nine months of the previous year as product recall and subsequent relaunches impacted domestic business.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.